There is 1 version of this bill. View text

Jump to: Summary | Actions Overview | All Actions | Titles | Subjects | Cosponsors | Committees | Related Bills

Summary (1)

There is one summary for S.2023. View summaries

Shown Here:
Introduced in Senate (09/10/2015)

Prescription Drug Affordability Act of 2015

This bill amends titles XVIII (Medicare) and XIX (Medicaid) of the Social Security Act to modify provisions related to the affordability of prescription drugs under the Medicare and Medicaid programs. Specifically, the bill:

  • requires the Centers for Medicare & Medicaid to negotiate lower prices on behalf of beneficiaries for drugs covered under Medicare Part D;
  • accelerates closure of the Medicare Part D coverage gap known as the "donut hole," under which beneficiaries who have reached a certain level of yearly drug costs become fully responsible for any additional drug costs up to a certain limit;
  • requires drug manufacturers to issue rebates for prescription drugs dispensed to eligible low-income individuals under Medicare or Medicaid; and
  • expands the application of certain prescription drug rebate requirements under Medicaid to include rebates for generic drugs.

The bill also amends the Federal Food, Drug, and Cosmetic Act to: (1) allow the importation by individuals of prescription drugs from Canada and, potentially, other countries; and (2) establish certain conditions on the award of market exclusivity with respect to drugs. Specifically, a drug manufacturer's market exclusivity shall be terminated if the manufacturer commits, or fails to report, a drug-related violation such as misbranding, illegal marketing, or fraud.

In addition, the bill amends the Federal Trade Commission Act to: (1) establish restrictions on certain anticompetitive patent settlements known as "pay-for-delay" agreements, which effectively block generic drug competition; and (2) allow the Federal Trade Commission to initiate proceedings to enforce these restrictions against any parties to such a settlement.

The bill also requires drug manufacturers to produce and share annual reports containing specified information related to domestic and foreign sales.


Actions Overview (1)

Date
09/10/2015 Introduced in Senate

All Actions (1)

Date
09/10/2015 Read twice and referred to the Committee on Finance.
Action By: Senate

Titles (2)

Short Titles:

Short Titles - Senate

Short Titles as Introduced:

Prescription Drug Affordability Act of 2015

Official Titles:

Official Titles - Senate

Official Titles as Introduced:

A bill to ensure greater affordability of prescription drugs.


Subjects (25)

  • Business records
  • Canada
  • Civil actions and liability
  • Competition and antitrust
  • Congressional oversight
  • Fraud offenses and financial crimes
  • Government information and archives
  • Health care costs and insurance
  • Health care coverage and access
  • Indian social and development programs
  • Inflation and prices
  • Intellectual property
  • Manufacturing
  • Medicaid
  • Medicare
  • Military medicine
  • Minority health
  • Prescription drugs
  • Public contracts and procurement
  • Research and development
  • Retail and wholesale trades
  • Trade agreements and negotiations
  • Trade restrictions
  • Veterans' medical care

Cosponsors (1)

* = Original cosponsor
CosponsorDate Cosponsored
Sen. Franken, Al [D-MN]* 09/10/2015

Committees (1)

Committees, subcommittees and links to reports associated with this bill are listed here, as well as the nature and date of committee activity and Congressional report number.

Committee / Subcommittee Date Activity Reports
Senate Finance09/10/2015 Referred to

Related Bills (7)

A related bill may be a companion measure, an identical bill, a procedurally-related measure, or one with text similarities. Bill relationships are identified by the House, the Senate, or CRS, and refer only to same-congress measures.